PTPA and cancer: Based on the pathophysiology of cancer cells, it can be suggested that effective therapeutic responses against them require simultaneous inhibition of kinase signaling pathways and the reactivation of their inhibitors, such as PP2A (Soofiyani et al., 2017; Westermarck, 2018).